|Bid||19.70 x 800|
|Ask||24.00 x 800|
|Day's Range||20.55 - 23.50|
|52 Week Range||17.35 - 25.21|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
EVANSTON, Ill. , June 25, 2018 /PRNewswire/ -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel, proprietary, synthetic small ...
Five more venture-backed biotechnology companies were set to begin public trading Thursday, after each priced within or above its expected range.
Inc. went public Wednesday during what should be one of the busiest weeks for biomedical IPOs in recent memory. Nine U.S. venture-backed biotechs had their debuts in the first quarter, according to VentureSource. Enthusiasm for biotech is fueling much of the activity.
EVANSTON, Ill. , June 20, 2018 /PRNewswire/ -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced ...
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . Eidos Therapeutics, Inc. (NASDAQ: EIDX ) will issue 6.25 million shares between $15 and $17 Wednesday on the Nasdaq. The ...